Almaarefa University
The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
EF

EA Fouad

Affiliation pending verification2015–2015
2Scopus documents
27citations
2h-index
0University-affiliated
Scopus total (all institutions)
ArticleOpen access201521citation

Characterization of Celecoxib-Loaded Solid Lipid Nanoparticles Formulated with Tristearin and Softisan 100

Tropical Journal of Pharmaceutical Research · vol. 14 (2) · 205-205

Purpose: To prepare solid lipid nanoparticles employing softisan 100 (SOFTI) or tristearin (TS) as solid lipid carriers for celecoxib (CXB) to overcome its dissolution challenge.Methods: The solid lipid nanoparticles (SLN) of CXB were prepared by ultrasonic melt-emulsification technique. SLN was characterized using differential scanning calorimetry (DSC), Fourier transform infra spectroscopy (FTIR), as well as for entrapment efficiency, particle size, zeta potential and CXB release.Results: The SLN formulations exhibited high CXB entrapment efficiency (91.6 % for SOFTI and 94.6 % for TS) while mean particle size was 181.0 ± 4.6 and 346.3 ± 3.8 nm for SOFTI and TS, respectively. The DSC thermograms showed the disappearance of CXB peak due to its molecular distribution in the lipid nanoparticles while FTIR spectra revealed physical interaction of CXB with the tested lipids. The tendency of SOFTI to liberate CXB in 24 h was higher than that of TS (55.5 ± 1.07 vs 49.2 ± 2.94 %, p < 0.05). Drug release was by non-Fickian mechanism.Conclusion: Formulation of CXB in SLN using TS or SOFTI produces sustained drug release delivery that can overcome the dissolution limitation of the drug and thus, improve its therapeutic efficacy.Keywords: Celecoxib, Solid lipid nanoparticles, Tristearin, Softisan, Dissolution limitation, Sustained drug release

celecoxibsolid lipid nanoparticlestristearinsustained drug release
ArticleOpen access20156citation

Embedment of Chlorpheniramine Maleate in Directly Compressed Matrix Tablets of Compritol and Kollidone SR

Tropical Journal of Pharmaceutical Research · vol. 14 (3) · 371-371

Purpose: To study the effect of compritol ATO888 and kollidon SR blend on the release of chlorpheniramine maleate (CPM) from its matrix tablets prepared by direct compression.Methods: Different ratios of compritol and kollidon SR (containing 50 % matrix component) in 1:1, 1:2, 1:3 and 3:1 ratios were formulated using direct compression. The formulations were organoleptically tested and investigated for CPM release.Results: The release kinetics showed Fickian diffusion mode for kollidone and anomalous release mechanism for compritol matrices. Combining compritol as a lipophilic material and kollidone produced a matrix with controlled drug release. Retardation of drug release rate depended on the ratio of compritol to kollidon. The lower the compritol component, the slower the drug release rate. CPM in matrix tablets containing compritol:kollidone SR in a ratio of 1: 3 achieved optimized sustained release, where 44 % of the drug was released within 8 h (versus 94.5 % for compritol and 54.2 % for kollidon matrix systems). The kinetics of drug release followed Fickian diffusion at low compritol concentration in the blend, reflecting the importance of pore formation. However, when compritol proportion was increased, drug release followed non-Fickian anomalous kinetics due to the water-repelling effect of compritol.Conclusion: Compritol content of CPM matrix tablets can be used to modulate drug release rate as well as release kinetics.Keywords: Chlorpheniramine maleate, Matrix tablets, Compritol, Kollidon, Drug release, Release kinetics

chlorpheniramine maleateKollidon SRmatrix tabletsdirect compression